Diffuse Large B-cell Lymphoma: Clinical Trials

22 trials for Diffuse Large B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 terminated. 22 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 122Terminated 22
Phase 26Terminated 6

Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1TerminatedPfizer62025-05-082026-05-08
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2TerminatedPfizer402023-08-302026-05-06
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2TerminatedPfizer62023-08-042025-09-05
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Loncastuximab Tesirine - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1TerminatedADC Therapeutics S.A.52023-07-282026-07-20
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
EZM0414 - Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
Phase 1TerminatedEpizyme, Inc.132022-05-312025-06-22
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedAntengene Corporation542022-04-072025-06-09
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
ME-401, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2TerminatedDeepa Jagadeesh132021-04-282025-02-07
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
SEA-TGT, sasanlimab, brentuximab vedotin - Non-small Cell Lung Cancer, Gastric Carcinoma
Phase 1TerminatedSeagen Inc.1332020-05-292025-02-10
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2TerminatedGenmab462020-03-132024-10-24
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Rituximab and Hyaluronidase Human, Cyclophosphamide, Vincristine - Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease
Phase 1TerminatedFred Hutchinson Cancer Center182019-10-242024-01-03
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Tisagenlecleucel, Ibrutinib - Diffuse Large B-cell Lymphoma
Phase 1TerminatedNovartis Pharmaceuticals102019-06-112023-01-31
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Venetoclax, AMG 176 - Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
Phase 1TerminatedAbbVie92019-03-182021-12-07
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
Loncastuximab Tesirine and Durvalumab - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Phase 1TerminatedADC Therapeutics S.A.132019-02-042021-10-26
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Loncastuximab Tesirine, Ibrutinib - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Phase 1 / Phase 2TerminatedADC Therapeutics S.A.1362018-12-012024-02-06
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Maplirpacept (PF-07901801), Azacitidine, Venetoclax - Lymphoma, Multiple Myeloma
Phase 1TerminatedPfizer1892018-05-142024-09-03
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present
Phase 1TerminatedFred Hutchinson Cancer Center32017-02-012020-11-23
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
MAK683 - Diffuse Large B-cell Lymphoma
Phase 1TerminatedNovartis Pharmaceuticals1392016-10-032025-08-11
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
Alisertib - Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Phase 1TerminatedUNC Lineberger Comprehensive Cancer Center12016-10-012017-11-20
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
SGN-CD19B - Non-Hodgkin Lymphoma, DLBCL
Phase 1TerminatedSeagen Inc.442016-02-012018-08-13
Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial
rituximab - Diffuse Large B-Cell Lymphoma
Phase 1TerminatedCelltrion12012-02-012014-07-23

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (22)  ·  Lymphoma (6)  ·  Lymphoma, Follicular (5)  ·  Lymphoma, Mantle-Cell (5)  ·  Lymphoma, Non-Hodgkin (4)  ·  Burkitt Lymphoma (3)  ·  Neoplasms (3)  ·  Recurrence (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Leukemia (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Lymphoma, T-Cell, Peripheral (2)  ·  Melanoma (2)  ·  Multiple Myeloma (2)

Broader conditions

Hemic and Lymphatic Diseases (22)  ·  Immune System Diseases (22)  ·  Immunoproliferative Disorders (22)  ·  Lymphatic Diseases (22)  ·  Lymphoproliferative Disorders (22)  ·  Neoplasms by Histologic Type (22)  ·  Lymphoma, B-Cell (21)  ·  Neoplasms (19)  ·  Lymphoma, Non-Hodgkin (18)  ·  Lymphoma (16)  ·  Hematologic Diseases (6)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Disease Attributes (5)  ·  DNA Virus Infections (3)

Interventions

Rituximab (7)  ·  Cyclophosphamide (3)  ·  Doxorubicin (3)  ·  Etoposide (3)  ·  Prednisone (3)  ·  Vincristine (3)  ·  loncastuximab tesirine (3)  ·  Lenalidomide (2)  ·  ibrutinib (2)  ·  venetoclax (2)  ·  Azacitidine (1)  ·  Brentuximab Vedotin (1)  ·  CT-P10 (1)  ·  Carmustine (1)  ·  Cytarabine (1)

Sponsors

Pfizer (4)  ·  ADC Therapeutics S.A. (3)  ·  Novartis Pharmaceuticals (3)  ·  Fred Hutchinson Cancer Center (2)  ·  Seagen Inc. (2)  ·  AbbVie (1)  ·  Antengene Corporation (1)  ·  Celltrion (1)  ·  Deepa Jagadeesh (1)  ·  Epizyme, Inc. (1)  ·  Genmab (1)  ·  National Cancer Institute (NCI) (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)

Countries

United States (19)  ·  Spain (7)  ·  France (4)  ·  Italy (4)  ·  South Korea (4)  ·  Germany (3)  ·  Japan (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Canada (2)  ·  China (2)  ·  Hong Kong (2)  ·  Netherlands (2)  ·  Taiwan (2)  ·  Australia (1)

Top investigators

Ajay Gopal (1)  ·  Andres Forero-Torres, MD (1)  ·  Christopher Dittus, DO (1)  ·  Deepa Jagadeesh, MD, MPH (1)  ·  Juan Pinelli, PA-C, MMSc (1)  ·  Manoj Menon, MD (1)  ·  Wonseog Kim, M.D., Ph.D. (1)  ·  Wyndham H Wilson, M.D. (1)

Results publications

PMID 28903943, PMID 39793445, PMID 40184567, PMID 41536778

NIH funding

2018 (3), 2019 (2), 2016 (1), P01CA044991 (1), P30CA015704 (1)